Partial
Partially Aligned
Patient Risk:
Medium
Summary
Partially aligned: the label excerpts support grapefruit juice increasing atorvastatin plasma concentrations via CYP3A4 inhibition and increased muscle pain/myopathy risk with larger/excessive grapefruit quantities. However, many mechanistic, quantitative, and causal-extension claims (e.g., furanocoumarin attribution, 'up to 40%', grapefruit-associated liver damage/kidney problems, categorical avoidance, and dosage adjustment) are not supported by the provided label text.
Category Scores
Accurate Statements
When grapefruit juice inhibits CYP3A4, atorvastatin (Lipitor) plasma concentrations can increase.
7.2 Grapefruit Juice: components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin.
The risk of muscle pain/myopathy is increased when taking LIPITOR with larger quantities of grapefruit juice (>1 liter).
17.1 Muscle Pain: risk increased with larger quantities (>1 liter) of grapefruit juice.
Unsupported Statements
Grapefruit juice contains furanocoumarin that can inhibit CYP3A4.
7.2 states components inhibit CYP3A4 but the provided excerpt does not name furanocoumarin.
CYP3A4 is responsible for breaking down many medications, including Lipitor (atorvastatin).
No supporting statement in the provided label excerpts about CYP3A4’s general role in metabolizing atorvastatin or 'many medications.'
Grapefruit juice can increase atorvastatin levels in the bloodstream by up to 40%.
No quantitative value (e.g., 40%) is present in the provided label excerpts.
Increased atorvastatin levels can lead to liver damage (including elevated liver enzymes and rare cases of liver failure) due to grapefruit juice.
The provided excerpts discuss liver enzyme abnormalities with statins and that grapefruit juice increases atorvastatin plasma concentrations, but do not state grapefruit juice/increased concentrations cause liver damage or rare liver failure.
Increased atorvastatin levels can lead to kidney problems (including via grapefruit juice).
Label excerpt links rhabdomyolysis to acute renal failure and notes renal impairment as a risk factor, but does not state grapefruit juice causes kidney problems.
Grapefruit juice can increase the levels of many medications, including statins like Lipitor.
Provided 7.2 excerpt addresses atorvastatin specifically, not 'many medications.'
It is recommended to avoid consuming grapefruit juice/products containing grapefruit juice if taking Lipitor.
The provided label excerpts discuss increased risk with excessive grapefruit quantities but do not provide a direct 'avoid grapefruit juice' recommendation.
Regularly monitoring liver enzymes and kidney function is recommended to ensure safe levels when consuming grapefruit juice while taking Lipitor.
Label excerpts provide liver function test timing generally and mention monitoring skeletal muscle effects in certain contexts, but do not specify monitoring liver enzymes and kidney function specifically due to grapefruit consumption.
A healthcare provider may need to adjust the Lipitor dosage to minimize the risk of adverse effects when consuming grapefruit juice.
No statement in the provided excerpts indicates dosage adjustment specifically for grapefruit juice.
Elevated levels of atorvastatin can lead to liver damage, including elevated liver enzymes.
The excerpt supports liver enzyme abnormalities with statins, and increased atorvastatin concentrations with grapefruit, but does not connect increased levels specifically to liver damage/elevated enzymes in the provided text.
Contradictions
Important Omissions
Label-relevant threshold detail for excessive grapefruit intake (e.g., 'especially with excessive grapefruit juice consumption (>1.2 liters per day)') is not explicitly reflected in the claims as a label-supported threshold.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims overextend label support by attributing grapefruit-related liver damage/kidney problems and recommending avoidance/monitoring and possible dose adjustment that are not directly supported by the provided excerpts, potentially leading to inaccurate risk framing or management expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported mechanistic/causal extensions and management-style recommendations (avoidance, monitoring specifically for grapefruit, dose adjustment), plus an unsupported quantitative 'up to 40%' magnitude and missing furanocoumarin attribution.
Suggested Improvement
Restrict statements to the provided label-supported points: grapefruit juice components inhibit CYP3A4 and can increase atorvastatin plasma concentrations; risk of muscle pain/myopathy is increased with larger/excessive grapefruit quantities (>1 liter and especially >1.2 L/day). Remove or rephrase unsupported specifics (furanocoumarin, 40%, grapefruit causing liver damage/kidney problems, categorical avoidance, grapefruit-specific monitoring, and dose adjustment).